Biotech Startups

Watershed is a bioinformatics platform for data-driven discovery and collaboration, handling biological data from sequencing to mass spectrometry. It is used by researchers to analyze and manage biological data.

2 investors

Wave Life Sciences develops RNA-targeting therapeutics using RNA-editing modalities and chemistry to treat rare and common diseases, with a clinical pipeline addressing Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity. It operates in the biotech and RNA medicines industry.

2 investors

Wavebreak develops a drug discovery platform targeting amyloid oligomers, toxic protein intermediates implicated in neurodegenerative diseases including Alzheimer's and Parkinson's. The company aims to address previously undruggable molecular pathways underlying neuronal death.

2 investors

Wayfinder develops RNA-targeting small molecule therapies using expertise in RNA biophysics, molecular biology, and machine learning to discover treatments for currently incurable diseases.

2 investors

WCG advances clinical trial efficiency and outcomes through research services and advisory support. The company serves the medical research and clinical trial industry.

2 investors

Wellthy Therapeutics develops digital therapeutics and clinical decision support tools for pharmaceutical and life science partners to address treatment adherence, patient outcomes, and eligibility challenges in complex clinical conditions and rare diseases. The company builds software-as-a-medical-device (SaMD) solutions, companion therapeutics, and remote patient monitoring platforms with medical-grade compliance.

2 investors

Women-led biotech company engineering high-performance protein-based textile fibers for fashion with sustainable alternatives to synthetic fibers.

2 investors

Woolsey Pharmaceuticals Pty Ltd (Woolsey AU) is the Australian subsidiary of Woolsey Pharmaceuticals, Inc., leading the company's corporate research and development activities in Australia. It operates in the pharmaceutical and biotech sector.

2 investors

Xella is a women's precision health platform that combines multi-omic diagnostic testing with personalized clinical care, analyzing biological data to detect signs of 130+ conditions that often go undiagnosed in women. It offers a membership including physician-reviewed results, personalized care plans, and support across fertility, reproductive, hormonal, metabolic, and longevity health, aimed at women in the U.S.

2 investors

Xenon is a neuroscience-focused biopharmaceutical company that discovers and develops ion channel modulators as therapeutics for neurological and psychiatric disorders. Its pipeline includes a Phase 3 program in epilepsy and depression for its lead candidate azetukalner, along with early-stage pain programs targeting sodium and potassium channels.

2 investors

Xerient is a biopharmaceutical company developing oncology treatments, with expertise in clinical trial design, radiation oncology, and translational cancer research for gastrointestinal malignancies.

2 investors

XGenomes develops genomic sequencing technology using fluorescent probes and machine learning to read genetic and epigenetic information at single-molecule resolution. The platform enables frequent, rapid, and low-cost screening for healthcare providers and patients to support early disease detection and personalized preventive medicine.

2 investors

Xibus Systems develops a pathogen detection system that combines engineered bio-molecules, super fluorescent nano-beads, custom bacterial growth media, and AI analytical software to detect disease-causing bacteria in foods and beverages. The company serves the food and beverage safety industry with faster, more sensitive bacterial detection.

2 investors

xMD Diagnostics develops laboratory instruments and consumables for molecular diagnostics, aimed at enriching samples for downstream molecular testing. It serves research, biopharmaceutical, and clinical (CLIA) laboratories to help pathologists, oncologists, and other physicians diagnose, monitor, and treat cancer and other genetic diseases.

2 investors

XN Health develops a medical device that uses phrenic nerve stimulation to prevent ventilator-induced lung injury in mechanically ventilated patients by inducing diaphragm contractions. The device is intended for healthcare providers managing patients requiring mechanical ventilation support.

2 investors

XWPharma develops internally discovered small-molecule medicines, focusing on new chemical entities that target time-regulated neurobiology to treat neurological conditions. The company runs its own drug discovery and clinical development programs aimed at high-value therapeutic markets.

2 investors

YPrime provides a clinical trial technology platform with patient engagement features (eConsent and eCOA) designed to accelerate trial timelines, improve data quality, and enhance participant experience for pharmaceutical companies, biotechs, and contract research organizations.

2 investors

Yellowbird Diagnostics develops plug-and-play imaging dyes for common medical imaging procedures, designed to reveal disease markers for earlier diagnosis of conditions affecting the brain, heart, and kidneys. The products are aimed at clinicians and patients needing early diagnosis of these diseases.

2 investors

Yuri develops in-house space labs and ground simulators that use microgravity for life sciences research, supporting drug development and cell-based therapies. It serves biotech and pharmaceutical customers, offering experiment platforms flown on the ISS and other space environments.

2 investors

Yuva Biosciences develops and licenses Y100, a cosmetic active ingredient that enhances mitochondrial health to reduce visible signs of aging for use in skincare and haircare products.

2 investors

Zentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.

2 investors

Zeroshot bio builds biology foundation models and AI pipelines that translate zebrafish drug-exposure data, combined with high-throughput single-cell RNA sequencing, into human pre-clinical insights. It generates compound rankings to accelerate hit-to-lead decisions for therapeutics developers.

2 investors

2 investors

ZYMEDI is a drug discovery company that partners through R&D joint ventures, strategic investments, and in-licensing arrangements. It works with collaborators across the pharmaceutical and biotechnology sector.

2 investors